Ligand Pharmaceuticals | LGND - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Agenus USD -221.22M 241.03M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
Baxter International USD 6.04B 2.85B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Enviri Corporation USD 233.18M 357.11M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Merck USD 18.17B 8.01B 2026-03
Pacira USD 172.75M 20.93M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Veracyte USD 119.99M 3.99M 2026-03